Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance.
The need for left ventricular mass (LVM) normalization to body size is well recognized. Currently used allometric exponents to normalize LVM may not account for the confounding effect of sex. Because sex is a strong determinant of body size and LVM, we hypothesized that these are subject to potential bias. We analyzed data from 7528 subjects enrolled in the Asklepios Study (n=2524) and the Multiethnic Study of Atherosclerosis (limited access data set; n=5,004) to assess metric relationships between LVM and body size, generate normative data for indexed LVM, and compare the ability of normalization methods to predict cardiovascular events. The allometric exponent that adequately described the LVM-body height relationship was 1.7 in both studies and significantly different from both the unity and 2.7, whereas the LVM-body surface area relationship was approximately linear. LVM/height(2.7) consistently demonstrated important residual relationships with body height and systematically misclassified subjects regarding the presence of LVH. LVH defined by LVM/height(1.7) was more sensitive than LVM/body surface area to identify obesity-related LVH and was most consistently associated with cardiovascular events and all-cause death. In contrast to current assumptions, LVM/height(2.7) is not an adequate method to normalize LVM for body size. We provide more appropriate normalization methods, normative data by 2D echocardiography and gradient-echo cardiac MRI, and cutoffs for defining LVH, along with prognostic validation data.
Chirinos
Julio A
JA
University of Pennsylvania/Philadelphia Veterans' Affairs Medical Center, Philadelphia, Pa, USA. Julio.chirinos@uphs.upenn.edu
Segers
Patrick
P
De Buyzere
Marc L
ML
Kronmal
Richard A
RA
Raja
Muhammad W
MW
De Bacquer
Dirk
D
Claessens
Tom
T
Gillebert
Thierry C
TC
St John-Sutton
Martin
M
Rietzschel
Ernst R
ER
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D049628:Body Size; D018450:Disease Progression; D015150:Echocardiography, Doppler; D005006:Ethnicity; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000208:ethnology / Q000209:etiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D014481:United States / Q000453:epidemiology
J Am Coll Cardiol. 1992 Nov 1;20(5):1251-60
1401629
Circulation. 2000 Jul 25;102(4):405-10
10908212
AJR Am J Roentgenol. 2006 Jun;186(6 Suppl 2):S357-65
16714609
Eur J Cardiovasc Prev Rehabil. 2007 Apr;14(2):179-91
17446795
Cancer Chemother Rep. 1970 Aug;54(4):225-35
5527019
Circulation. 1998 Dec 8;98(23):2538-44
9843460
Am J Hypertens. 2005 Oct;18(10):1288-93
16202850
J Am Coll Cardiol. 1995 Mar 15;25(4):879-84
7884091
Am J Hypertens. 2005 Feb;18(2 Pt 1):191-6
15752946
J Am Coll Cardiol. 2008 Dec 16;52(25):2148-55
19095132
Hypertension. 1997 May;29(5):1095-103
9149672
Am J Cardiol. 1994 Sep 1;74(5):487-91
8059731
Int J Cardiovasc Imaging. 2010 Apr;26(4):459-68
20107905
Circulation. 1997 Apr 1;95(7):1837-43
9107171
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
16376782
Int J Epidemiol. 2003 Aug;32(4):614-6
12913038
Ann Intern Med. 1991 Mar 1;114(5):345-52
1825164
Am J Epidemiol. 2002 Nov 1;156(9):871-81
12397006